In recent years, “olaparib” and “double-blind” burst from 2020 to 2022, denoting the evaluation of the efficacy and safety of Olaparib in both monotherapy and combination therapy among patients with BRCA1/2-mutant breast cancer (74–77). This evidence concerns the gene BRCA1 and breast carcinoma.